Jane Street Group LLC Trims Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Jane Street Group LLC reduced its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 52.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 73,487 shares of the company’s stock after selling 79,577 shares during the period. Jane Street Group LLC owned approximately 0.05% of Compass Therapeutics worth $135,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the period. Rhumbline Advisers lifted its stake in Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after purchasing an additional 12,315 shares in the last quarter. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at approximately $30,000. Finally, Bank of New York Mellon Corp raised its position in shares of Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after buying an additional 31,433 shares during the period. 68.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. D. Boral Capital reiterated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.95 on Tuesday. The firm has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.46. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.68. The stock has a market cap of $268.30 million, a price-to-earnings ratio of -5.27 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities analysts expect that Compass Therapeutics, Inc. will post -0.35 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.